Alzheimer’s

How The Medical System Is Failing People With Down Syndrome And Alzheimer’s Disease

Over just the past few decades, the life expectancy of people with Down Syndrome (DS) has increased from less than 30 years to nearly 60. But for many, that remarkable advancement comes at a high price. As they live longer, up to ninety percent of people with DS will have Alzheimer’s Disease. It is, in fact, the leading cause of death [...]

By |2022-02-10T13:53:33-05:00February 10th, 2022|dementia, Uncategorized|0 Comments

Medicare Won’t Pay for Controversial Alzheimer’s Drug Aduhelm Without A New Trial

In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial. In bureaucratic language: “Monoclonal antibodies directed against amyloid for the treatment of [Alzheimer’s Disease] provided outside of the CMS approved randomized controlled trials and trials supported [...]

By |2022-01-11T17:46:04-05:00January 11th, 2022|dementia|0 Comments

What’s Behind Biogen’s Move To Cut Prices On Its Controversial Alzheimer’s Drug Aduhelm?

This week, drugmaker Biogen made a stunning announcement: It is going to cut in half the price of its controversial Alzheimer’s drug Aduhelm. Instead of selling the infusion drug for $56,000 annually to a typical user it will charge $28,000-a-year. It is, to say the least, unusual, for the maker of a potential blockbuster drug to cuts its price just [...]

By |2021-12-23T14:28:34-05:00December 23rd, 2021|dementia|0 Comments

Will Medicare Pay For The New Alzheimer’s Drug?

Last month, The Food and Drug Administration (FDA) approved a controversial new drug to treat people with Alzheimer’s disease. But even though the FDA allowed the drug to be sold, Medicare is not required to pay for it. And yesterday, the Centers for Medicare & Medicaid Services (CMS) began a process to determine whether Medicare will establish a national coverage [...]

By |2021-07-13T13:57:06-04:00July 13th, 2021|dementia|0 Comments

FDA’s Approval Of A New Alzheimer’s Drug Shows What’s Wrong With The Way We Care For Frail Older Adults

FDA’s decision last week to approve a new “Alzheimer’s disease treatment,” and the buzz that surrounds it, is a symptom of all that is wrong with the way we care for frail older adults in the US. Rather than providing the supports that people with chronic conditions desperately need, and that evidence shows works, we prefer to chase butterflies. In [...]

By |2021-06-15T11:54:04-04:00June 15th, 2021|long-term care, Uncategorized|0 Comments

What Does FDA’s Approval Of A New Alzheimer’s Drug Mean?

In a highly controversial decision, the FDA gave accelerated approval to the first drug that could slow the progression of Alzheimer’s disease. But the approval does not say the FDA thinks the drug actually will treat the disease. Rather, FDA carefully states that the drug, with the chemical name aducanumab and the brand name Aduhelm, reduces a substance on the [...]

By |2021-06-07T17:50:37-04:00June 7th, 2021|dementia|5 Comments

Covid-19 Has Made Caregiving Harder, But Isn’t Making Americans More Likely To Plan For Their Old Age

The covid-19 pandemic has increased the burden on family caregivers and made Americans more insistent than ever on receiving their own care at home, rather than in a long-term care facility. Yet, they are in more denial than before the pandemic about the likelihood they or a loved one will need  personal assistance at some time in their lives. As [...]

By |2020-10-27T11:49:02-04:00October 14th, 2020|family caregivers|0 Comments

The Anti-Alzheimer’s BOLD Act Isn’t. But It Could Be A Step In The Right Direction

Last week, President Trump signed into law the BOLD Infrastructure for Alzheimer’s Act, a measure aimed at building a public health model to fight Alzheimer’s disease and other dementias. The law would authorize up to $100 million over five years to improve public education, support health and social service agencies’ dementia initiatives, and collect and disseminate data about cognitive decline. [...]

By |2019-01-09T11:00:47-05:00January 9th, 2019|dementia|0 Comments

New Congressional Budget Bill Boosts Spending For Senior Services Programs

The huge 2018 budget bill Congress passed last week includes significant new money for dementia research and modest additional funding for many programs aimed at assisting frail older adults. The final $1.3 trillion bill was a dramatic about-face for President Trump and House Republicans, whose own budget plans would have slashed or even eliminated funding for many seniors’ programs. The [...]

By |2018-03-28T13:05:23-04:00March 28th, 2018|Federal senior services programs|0 Comments

Are We Getting Closer To A Cheap, Simple Alzheimer’s Test? What Would It Mean?

Have you seen the stories about new tests for Alzheimer’s Disease that supposedly are just around the corner? The claims: A simple blood test, an eye test, even a smell test that could show that you are at high risk for Alzheimer’s decades before you develop symptoms. They are promising, scary, and--so far--premature. Sadly, we’ve seen this movie before. Like [...]

By |2017-08-23T07:59:12-04:00August 23rd, 2017|dementia|0 Comments